In 2021, Li et al. reported that trastuzumab deruxtecan achieved ORR of 55%, mDoR of 9.3 months, mPFS of 8.2 months, and median overall survival (mOS) of 17.8 months in patients with HER2-mutated NSCLC (DESTINY-Lung01)76. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.